Moleculin Biotech to Offer 4.56M Shares, Warrants; Raises $9.1M

Moleculin Biotech, Inc. filed an S-1 registration statement for a "reasonable best efforts" public offering of up to 4,566,210 shares of common stock, 4,566,210 pre-funded warrants, and 13,698,630 common warrants. The offering is expected to raise approximately $9.1 million in net proceeds, which will be used for clinical development of Annamycin and working capital. The company also announced positive preliminary interim efficacy results from its pivotal Phase 2/3 MIRACLE trial for R/R AML, showing CR rates of 43% and 36% in treatment arms versus 12% in the control arm, and CRc rates of 50% and 57% versus 29% in the control arm.